New research published in the Journal of the National Comprehensive Cancer Network found that people with newly-diagnosed hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer were more likely to receive timely, guideline-concordant treatment, and have longer survival in states that participate in Medicaid expansion under the Affordable Care Act.
UNC Lineberger Comprehensive Cancer Center has been awarded up to $28 million by the Advanced Research Projects Agency for Health to lead the development of a next-generation clinical trial for breast cancer that has spread to other parts of the body.
